Material and Methods: Between 1992 and 2005, 215 patients with advanced breast cancer received radiotherapy due to poor respond to adjuvant chemotherapy in Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland. Median age was 57 years. Sixty three (29%) patients were premenopausal, 85 were Er(+), 74 (34.5%) were Er(−), 54 (25%) had not known receptor status. Ninety eight percent of patients were in III stage disease. All had radiotherapy to the breast. Supraclavicular or axillar nodes were not irradiated in 10 (4.5%) patients. Median dose to breast, breast tumor, axillar and supraclaviular nodes were 60 Gy (44−80 Gy), 70 Gy (44−81 Gy), 60 Gy (44−81 Gy), 50 Gy (42−72 Gy) respectively. After radiotherapy 137 patients (64%) had additional hormonotherapy and 51 (24%) had ultimate mastectomy.

Results: In hundred and two (47%) patients distant failure was found. Among those, 49 patients (48%) had simultaneously local failure. Thirty three (15%) patients had sole local failure. The five year locoregional control (LRC) was observed in 63% of patients. The five-year disease-free survival (DFS) and metastases-free survival (MFS) were 44% and 51% respectively. Mastectomy and hormonotherapy significantly and independently influenced treatment results. Patients who ultimately underwent mastectomy had significantly higher LRC ($p < 0.001$), longer DFS ($p < 0.001$) and MFS ($p < 0.001$). Hormonotherapy significantly increased LRC ($p < 0.001$) and DFS ($p = 0.02$).

Conclusions: High-dose radiotherapy should be given to the patients with advanced, nonoperable breast cancer who did not respond to neoadjuvant chemotherapy, because long-term tumor control could be obtain in over half of them, mastectomy can be reconsidered then. Maintenance hormonotherapy and/or ultimate mastectomy improve treatment results.

239 Poster

10-year results of intraoperative electron radiotherapy (IOERT) in boost modality in breast cancer patients treated with breast conserving surgery

R. Reitsamer[1], M. Kopp[1], G. Fastner[1], C. Menzel[1], S. Glueck[1], F. Merz[1], P. Kopp[1], H. Deutschmann[1], F. Peintinger[2], F. Sedlmayer[1]. *[1]University Hospital Salzburg, Breast Center Salzburg, Salzburg, Austria; [2]General Hospital Leoben, Department of Gynecology, Leoben, Austria*

Introduction: The aim of this nonrandomized study was to compare ipsilateral breast tumor recurrence rates in patients with invasive breast cancer, who had been treated with breast conserving surgery and whole breast irradiation and conventional boost or intraoperative electron radiotherapy boost (IOERT).

Patients and Methods: 378 patients were included in the study, 188 patients in group 1 (conventional boost) and 190 patients in group 2 (IOERT boost). Patients were comparable with regard to age, menopausal status, tumor size, histological type, grading and axillary lymph node status. Included were patients with invasive breast cancer pT1 and pT2, N0, N1, N2, M0, and breast conserving surgery with clear margins >3 mm. Excluded were patients with DCIS only, patients with invasive breast cancers larger than pT2, patients after primary systemic therapy and patients with multicentric disease. All patients (group 1 and group 2) received postoperative whole breast irradiation of 51–56.1 Gy. Group 1 received postoperative electron boost irradiation of 12 Gy after whole breast irradiation and group 2 received one intraoperative electron boost of 9 Gy in a single fraction during surgery before whole breast irradiation.

Results: The 10-years actuarial rates of ipsilateral breast tumor recurrence (IBTR), true local recurrence (TLR), distant recurrence (DR) and disease free survival (DFS) were 7.1% (95% CI, 3.2–11.0%), 4.8% (95% CI, 1.5−8.0%), 14.2% (95% CI, 9.1–19.4%) and 82.4% respectively in group1 and 2.7% (95% CI, 0.0−5.9%, $P = 0.062$), 0.7% (95% CI, 0.0−2.0%, $P = 0.016$), 13.6% (95% CI, 5.0–22.2%, $P = 0.90$) and 84.0% ($P = 0.76$) respectively in group 2.

Conclusion: Patients treated with IOERT boost and whole breast irradiation achieve excellent local control rates at 10 years and exhibit statistically significant decreased true local recurrence rates compared to patients treated with whole breast irradiation and conventional electron boost.

240 Poster

Postmastectomy adjuvant radiotherapy in patients with less than four axillary lymph nodes: a retrospective analysis

S. Saha[1], A. Gangopadhyay[1]. *[1]Medical College Hospital Kolkata, Radiotherapy, Kolkata (Calcutta), India*

Background: There is no consensus as yet regarding post mastectomy radiotherapy (PMRT) for patients with <5 cm tumor having less than 4 axillary lymph nodes although the same exists for patients with 4 or more positive nodes. But several recent publications (20 year result of British Columbia Study and DBCG 82 Protocol published by Overgaard et al) challenge 'this separation between 1 to 3 and 4 or more positive axillary nodes as a relevant descriptor of indication of PMRT'. This was the impetus that led us to review and analyze retrospectively from our institute data, the impact of post mastectomy radiotherapy (PMRT) in this controversial group.

Material and Method: Records of 785 patients with T1, T2 tumors who were registered in our department following mastectomy with axilla dissection with <4 positive axillary nodes between 2002 and 2007 were analyzed. 127/785 patients had 8 or less nodes dissected (as found in histopathology reports) and as such were excluded from the analysis. Of the remaining 658 patients, **528** received no PMRT, as per consensus. But **130** patients, as found in record, had received PMRT (possibly they appeared to be non-compliant regarding follow up). Locoregional recurrence, distant failure, disease free survival and overall survival of these 130 patients were studied and compared with 528 patients who were not offered PMRT.

As per erstwhile institutional policy, all patients had received FAC chemotherapy for 6 cycles. Receptor positive patients (164/528 of non-PMRT and 42/130 of PMRT subsets) were on Tamoxifen or an A.I.

Results: At a median interval of 30 months 132/528 patients not receiving PMRT suffered locoregional recurrence (chest wall recurrence alone in 36/528, supraclavicular recurrence in 81/528, chest wall + supraclavicular recurrence in 15/528, axillary and IMN recurrence in none). On the contrary only 4/130 patients receiving PMRT had locoregional failure ($p < 0.0001$). Distant metastasis was recorded in 37/528 of non PMRT subset and 8/130 of PMRT subset (p=NS). Survival data till September 2008 showed 4/130 deaths among PMRT subset against 26/528 of non PMRT (p=NS). 121/130 of PMRT are living without disease, contrary to 432/528 of non PMRT ($p = 0.001$).

Conclusions: This retrospective analysis revealed statistically significant reduction in locoregional recurrence as well as increased disease free survival with PMRT in T1 or T2 breast cancer patients with 1−3 positive axillary nodes. Deprivation of adjuvant radiotherapy for this subset of patients appears to be unjustified.

241 Poster

Loco-regional recurrence after breast conservative surgery and radiotherapy to the breast in patients with T1−2 disease and 1−3 positive axillary nodes

C. Aristei[1], M.C. Leonardi[2], F. Stracci[3], I. Palumbo[1], A. Luini[4], G. Viale[5], A. Cavaliere[6], E. Cristallini[7], R. Orecchia[8]. *[1]Perugia General Hospital, Radiation Oncology, Perugia, Italy; [2]European Institute of Oncology, Radiation Oncology, Milano, Italy; [3]University of Perugia, Department of Surgical and Medical Specialties and Public Health, Perugia, Italy; [4]European Institute of Oncology, Senology Division, Milano, Italy; [5]European Institute of Oncology, Pathology Division, Milano, Italy; [6]University of Perugia, Pathological Anatomy, Perugia, Italy; [7]"S. Giovanni Battista" Hospital, Pathological Anatomy, Foligno, Italy; [8]European Institute of Oncolgy, Radiation Oncology, Milano, Italy*

Aim: To assess relapse of invasive breast cancer after conservative surgery (CS), radiotherapy (RT) to the breast, adjuvant chemo (CT)- and/or hormone-therapy.

Patients and Methods: 575 patients (median age 53.6 years; range 25−82) with T1-T2 breast cancer and 1−3 (median 1) positive axillary nodes underwent CS. A median of 19 nodes (range 8−63) were examined (<10 nodes in 12 patients; unknown number in 1). Estrogen and progesterone receptors were respectively positive in 442 and 345 cases, negative in 107 and 200, unknown in 26 and 30. Lymphovascular invasion was present in 152 cases, absent in 417, not determined in 6. All patients received whole breast RT with standard fractionation (1.8−2 Gy/fraction up to 50.4−50 Gy) with boost (dose range: 10−16 Gy) to tumor bed in 561 (97.6%). Draining nodes were never irradiated. Adjuvant CT was given to 459 (80.2%) patients, tamoxifen to 432 (75.1%) and no adjuvant systemic therapy to 3. Kaplan Meter curves and log-rank test were used for survival analyses and Cox model for multivariate analyses.

Results: Median follow-up was 7.3 years (range 1.8−10). After a median of 4.4 years (range 1.7−9.1) from CS 24 patients (4.17%) had nodal relapses in the supraclavicular region (13), axilla (2), internal mammary nodes (2), more than 1 site (3). The 10 year nodal relapse-free survival was 94% (CI 95% 90.6–96.2). After a median of 4.2 years (range 1.0−9.3) from CS 27 patients (4.7%) had local relapse. The 10 year local relapse-free survival was 92.8% (CI 95% 89.0–95.3). In univariate analysis risk factors were higher grading and negative/unknown receptor status for nodal relapse; positive, close/unknown margin status and positive/excised node ratio for local relapse. In multivariate analysis, G3 tumors significantly increased the risk of nodal relapse (HR 5.1, 95% CI: 1.6–13.8 vs G1-G2 cases). ER and/or PgR positivity afforded significant protection (HR 0.33, CI: 0.14–0.78). Increased risk of local relapse was associated with close and positive margins (HR 3.2, 95% CI: 1.3−7.5) and positive to examined axillary node ratio (HR 1.006, 95% CI: 1.001–1.01). Older age